POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

Lung Neoplasms Clinical Trial

Official title:

A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects With Oligometastatic Tumors in the Lung

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05299606
• Other study ID #: NEU_2020_03
• Status: Recruiting
• Phase: N/A
• Start date: October 24, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2024
• Source: Ethicon, Inc.
• Contact: Erin Meyers, MBA
• Phone: 937-681-0322
• Email: eprifog1[@]its.jnj.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone. The primary endpoint is Technique Efficacy, assessed 30-days post-ablation via CT imaging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 145
• Est. completion date: December 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

INCLUSION CRITERIA:

• Signed informed consent.
• Subjects greater or equal to 22 years old.
• Performance status 0-2 (Eastern Cooperative Oncology Group classification (ECOG).
• Willing to fulfill all follow-up visit requirements.
• Subjects with at least one oligometastatic lung tumor where the primary tumor is controlled (in the opinion of the investigator or treating oncologist).
• Oligometastatic lung tumor(s) planned to be ablated in the outer two-thirds of the lung and not closer than 1cm to the pleura.

EXCLUSION CRITERIA:

• Pregnant or breastfeeding.
• Subjects with thoracic implantable devices, including pacemakers or other electronic implants.
• Chronic, continuous ventilator support, which uses bi-level positive airway pressure (PAP) to improve lung function for severe conditions. (However, intermittent PAP, for non-pulmonary conditions, such as sleep apnea, is permitted).
• Prior pneumonectomy.
• Severe bronchiectasis (with FEV1 <30%) or disease deemed to be too severe in the opinion of the investigator.
• Platelet count = 50,000/mm3.
• Subjects with uncorrectable coagulopathy at time of screening.
• Subjects medically unable to stop anti-platelet agents (e.g., aspirin, clopidogrel, prasugrel, ticagrelor) at least 5 days prior to the procedure through 48-72 hours after the procedure.
• Subjects medically unable to stop warfarin at least 3-5 days prior to the ablation procedure, or until INR < 1.5, through 48-72 hours after the procedure. On the day of the procedure, subjects with an INR > 1.5 cannot have the procedure completed that day but may be rescheduled or postponed.
• Subjects medically unable to stop anticoagulants (e.g., rivaroxaban, apixaban, dabigatran, endoxaban) at least 3 days prior to the ablation procedure through 48-72 hours after the procedure.
• Expected survival less than 6 months in the opinion of the investigator and/or treating oncologist.
• Subjects with known or suspected brain metastases.
• Subject has had any radiation (i.e., SBRT or EBRT) to the intended ablation zone.
• Endobronchial tumors proximal to and including the segmental airways.
• Lung ablation, surgical resection therapy, radiotherapy, or any other treating procedure within 30 days prior to the planned study ablation procedure or those who plan to receive a lung ablation, surgical resection, or radiation therapy on the ablated lung side before completing the primary endpoint assessment (30 days post-ablation).
• Systemic therapy (e.g., chemotherapy, targeted drug therapy, or immunotherapy) within 14 days prior to the planned study ablation procedure or those who plan to receive systemic therapy before completing the primary endpoint assessment (30 days post-ablation).

Related Conditions & MeSH terms

• Lung Neoplasms

Intervention

Device:
• Transbronchial Microwave Ablation
Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Universite de Montreal	Montreal	Quebec
Canada	University of Toronto	Toronto	Ontario
Hong Kong	Prince of Wales Hospital	Sha Tin
United States	Cleveland Clinic	Cleveland	Ohio
United States	UCONN Health	Farmington	Connecticut
United States	MD Anderson	Houston	Texas
United States	Minnesota Lung Center	Minneapolis	Minnesota
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	FirstHealth Moore Regional Hospital	Pinehurst	North Carolina
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Technique Efficacy	Ablation of the target tumor(s) with the ablation zone completely overlapping or encompassing the entire target tumor(s) using CT imaging.	30 days (-7 to +14 days) post-ablation
Secondary	Technical Success	A complete tumor ablation with a surrounding minimal margin as assessed by cone beam CT imaging.	Immediately post-ablation (day 0)
Secondary	Navigational Success	Successful navigation to the targeted peripheral lung tumor(s) as confirmed using cone beam CT.	During navigation (day 0)
Secondary	Local Tumor Progression	Recurrence of the originally ablated target tumor(s) within or abutting the ablation zone using the 30-day post-ablation imaging as the baseline.	12-month visit
Secondary	Local Tumor Progression Free Survival	Time from the ablation until local tumor(s) progression or death, whichever occurs first.	12-month visit
Secondary	Progression Free Survival	Time from the original ablation until tumor(s) progression or death, whichever occurs first (includes local, regional, or distant progression).	12-month visit
Secondary	Disease (cancer) Specific Survival	Time from the original ablation until death from the treated primary malignancy.	12-month visit
Secondary	Overall Survival	Time from the original ablation until subject death (includes death from any cause).	12-month visit
Secondary	Repeat Ablation Efficacy Rate	Rate of original tumors that have been re-ablated successfully (i.e., Technical Success of tumors that have been re-ablated out of all original tumors that have been re-ablated).	12-month visit
Secondary	Change in Pulmonary Function Tests (Spirometry I)	Change in all available (i.e., what is site standard-of-care) spirometry tests from pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation.; Spirometry tests are non-invasive and measure how much air one can breathe in and out of one's lungs, as well as how easily and fast one can the blow the air out of one's lungs. These tests include FVC (forced vital capacity, % of predicted), FEV1 (forced expiratory volume, % of predicted), FEV1/FVC (% ratio), and FEV 25-75 (average flow at which 25% has been exhaled through the point which 75% has been exhaled), all of which are expressed as a percentage.	12-month visit
Secondary	Change in Pulmonary Function Tests (Spirometry II)	Change in peak expiratory flow and maximum ventilation volume spirometry tests from pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation.; Peak Expiratory Flow is the maximal rate that one can exhale during a short maximal expiratory effort after a full inspiration and Maximum Ventilation Volume is the maximum minute volume of ventilation that one can maintain for 12-15 seconds. Both tests are expressed as L/min.	12-month visit
Secondary	Change in Pulmonary Function Tests (Diffusion Capacity)	Change in diffusion capacity from the pre-ablation baseline value to values at 3-months, 6-months, and 12-months post-ablation.; The diffusion capacity test measures the volume of carbon monoxide transferred from the lung to blood and is measured in ml/min/mmHg and put into a percentage (% of predicted).	12-month visit
Secondary	Change in Pulmonary Function Tests (Lung Volume)	Change in lung volume from the pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation.; The lung volume tests include plethysmographic TLC (total lung capacity), plethysmographic FRC (functional residual capacity), plethysmographic RV (residual volume), gas dilution TLC, gas dilution FRC, and gas dilution RV. A plethysmograph measures changes in volume within an organ and a gas dilution test may determine lung volumes that cannot be determined from simple spirometry. All assessments are collected in liters (L) and put into a percentage (% of predicted).	12-month visit
Secondary	Change in EORTC QLQ-C30	Change in quality of life scores per the validated EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 questionnaire from pre-ablation baseline scores to scores at 3-months, 6-months, and 12-months post-ablation. The questionnaire asks cancer patients to choose a response that most closely describes them for 30 questions on a scale from 1-4 (1 being 'not at all', 2 being 'a little', 3 being 'quite a bit' and 4 being 'very much). The 30 questions are separated into sections for 'general quality of life', 'during the past week', and 'overall health and quality of life'.	12-month visit
Secondary	Change in EORTC QLQ-LC13	Change in quality of life scores per the validated EORTC (European Organization for Research and Treatment of Cancer) QLQ-LC13 questionnaire from pre-ablation baseline scores to scores at 3-months, 6-months, and 12-months post-ablation. The questionnaire asks lung-cancer patients to choose a response that most closely describes them for 13 questions on a scale from 1-4 (1 being 'not at all', 2 being 'a little', 3 being 'quite a bit' and 4 being 'very much). The 13 questions are all about symptoms and problems experienced during the past week.	12-month visit